Tryptophan immunoadsorption for the treatment of autoimmune encephalitis
Version of Record online: 3 MAR 2014
© 2014 The Author(s) European Journal of Neurology © 2014 EAN
European Journal of Neurology
Volume 22, Issue 1, pages 203–206, January 2015
How to Cite
Köhler, W., Ehrlich, S., Dohmen, C., Haubitz, M., Hoffmann, F., Schmidt, S., Klingel, R., Kraft, A., Neumann-Haefelin, T., Topka, H., Stich, O., Baumgartner, A. and Fassbender, C. (2015), Tryptophan immunoadsorption for the treatment of autoimmune encephalitis. European Journal of Neurology, 22: 203–206. doi: 10.1111/ene.12389
- Issue online: 13 DEC 2014
- Version of Record online: 3 MAR 2014
- Manuscript Accepted: 28 JAN 2014
- Manuscript Received: 24 SEP 2013
- autoimmune encephalitis;
- NMDAR autoantibody;
- plasma exchange;
- therapeutic apheresis;
- tryptophan immunoadsorption
Background and purpose
Detection of autoantibodies against neuronal surface antigens and their correlation with the pattern and severity of symptoms led to the definition of new autoimmune-mediated forms of encephalitis and was essential for the initiation of immunotherapies including plasma exchange. The elimination of autoantibodies using selective immunoadsorption (IA) is a pathophysiologically guided therapeutic approach but has not yet been evaluated in a separate analysis.
A retrospective analysis was performed of patients with autoimmune encephalitis who were treated with tryptophan IA in six neurological clinics between 2009 and 2013. The modified Rankin scale (mRS) was used to evaluate neurological status before and after IA.
Data on 13 patients were documented. Twelve patients were positive for specific autoantibodies (NMDA-R, GABA, GAD, Lgl1). Patients received a series of a median of six IA treatments. Median mRS of all patients was 3.0 before IA and 2.0 after IA (P < 0.001). Eleven patients improved by at least one point in mRS after IA.
For autoimmune-mediated forms of encephalitis rapid elimination of autoantibodies with selective IA seems to be an effective therapeutic option as part of multimodal immune therapy.